U.S. Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
10.59-0.03 (-0.28%)
At close: 4:00PM EDT
10.30 -0.29 (-2.74%)
After hours: 07:59PM EDT
Full screen
Loading interactive chart...
  • Brooklyn Immuno Reports Inducement Grants
    GlobeNewswire

    Brooklyn Immuno Reports Inducement Grants

    BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on July 15, 2021, Jay Sial was granted a non-qualified stock option covering 71,000 shares of Brooklyn’s common stock (the “Time-Based Option”) and a restricted stock unit co

  • Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
    GlobeNewswire

    Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

    Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the Transaction and Future Plans NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and m

  • Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
    GlobeNewswire

    Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer

    NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021. “Jay has a long and impressive history managing the finances of multiple health systems and hos